The Cancer Drug Development Forum is proud to announce its selection as an ad hoc representative of the Multi-Stakeholder Platform Advisory Group (MSP AG) under the Accelerating Clinical Trials in the EU (ACT EU).
The ACT EU initiative is run by the European Commission, the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) to transform the EU into a region that supports clinical trial development and enables collaboration and innovation at all stages of the clinical research lifecycle.
As part of its efforts, the ACT EU’s Multi-stakeholder platform (MSP) will function as a vehicle for clinical trials stakeholders and regulators to come together, voice their views and collaborate to improve the clinical trials environment for European patients and citizens. The MSP will enable dialogue with regulators through the creation of a MSP Advisory Group, in which the CDDF is selected to take part.
We are excited to embark on this collaborative endeavor and look forward to the year 2024, advancing our mission of accelerating the development and delivery of oncology drugs to patients.
Read more about the ACT EU and its work plan, click here: https://www.ema.europa.eu/en/human-regulatory-overview/research-and-development/clinical-trials-human-medicines/accelerating-clinical-trials-eu-act-eu